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A BRCA2 prostate cancer cluster region (PCCR) was recently proposed (c.7914 to 3’) wherein 54 
pathogenic variants (PVs) are associated with higher prostate cancer (PCa) risk than PVs elsewhere in 55 
the BRCA2 gene. Using a prospective cohort study of 447 male BRCA2 PV carriers recruited in the UK 56 
and Ireland from 1998 to 2016, we estimated standardised incidence ratios (SIRs) compared to 57 
population incidences and assessed variation in risk by PV location. Carriers of PVs in the PCCR had a 58 
PCa SIR of 8.33 (95% confidence interval [CI] 4.46-15.58) and were at higher risk of PCa than carriers 59 
of other BRCA2 PVs (SIR=3.31, 95% CI 1.97-5.57; hazard ratio [HR]=2.34, 95% CI 1.09-5.03). PCCR PV 60 
carriers had an estimated cumulative PCa risk of 44% (95% CI 23%-72%) by age 75 and 78% (95% CI 61 
54%-94%) by age 85. Our results corroborate the existence of a PCCR in BRCA2 in a prospective 62 
cohort. 63 
 64 
Patient summary 65 
 66 
In this report we investigated whether the risk of prostate cancer for men with a harmful mutation 67 
in the BRCA2 gene differs based on where in the gene the mutation is located. We found that men 68 
with mutations in one region of BRCA2 had a higher risk of prostate cancer than men with mutations 69 
elsewhere in the gene.  70 
 71 
  72 
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We recently reported prostate cancer (PCa) risk estimates for pathogenic variants (PVs) in BRCA2, 73 
based on a prospective cohort of male carriers [1]. Variability in cancer risks due to genotype-74 
phenotype correlations may allow for more individualised counselling and screening. We noted that 75 
PVs within the so-called ovarian cancer cluster region (OCCR) in exon 11 of the gene [2–4] were 76 
associated with lower PCa risk than other BRCA2 PVs [1,3,4]. PVs in the OCCR have been consistently 77 
shown to be associated with increased ovarian cancer risk but decreased breast cancer risk [2,3,5,6], 78 
although the precise boundaries of the OCCR [3,5] and the mechanisms behind this risk variation 79 
remain uncertain. It has been proposed that the likelihood that a PV triggers nonsense-mediated 80 
mRNA decay varies by genomic region [7,8], so that OCCR PVs might produce a truncated or 81 
alternatively spliced protein whose capability to suppress tumours varies by cancer type [2,3,5,7,8], 82 
but there is currently no experimental support for this hypothesis [7]. Shortly after the publication of 83 
our manuscript, Patel and co-workers proposed the existence of a prostate cancer cluster region 84 
(PCCR) at the 3’ end of BRCA2, based on retrospective cohort data [8]. This retrospective study 85 
reported that men with BRCA2 PVs in the proposed PCCR have a higher risk of PCa (hazard ratio 86 
[HR]=1.78, 95% confidence interval [CI] 1.25-2.52), particularly Gleason score≥8 PCa (HR=3.11, 95% 87 
CI 1.63-5.95), compared to men with PVs in the reference region c.1001 to c.7913, but did not 88 
present estimates of the absolute PCa risk for PCCR PV carriers [8]. In order to substantiate or refute 89 
this association, and to provide direct estimates of the absolute risk of PCa for carriers of BRCA2 90 
PCCR PVs, we have reanalysed our prospective data.  91 
 92 
The prospective cohort comprised 447 male BRCA2 PV carriers who were recruited to the EMBRACE 93 
study (http://ccge.medschl.cam.ac.uk/embrace/) through clinical genetics centres in the UK and 94 
Ireland between 1998 and 2016 at median age of 51.4 yr (inter-quartile range 41.5-63.6 yr). The 95 
participants were counselled with regard to their PV. Detailed information on the cohort and on 96 
inclusion criteria, data collection, follow-up, and statistical analysis approach, is available in our 97 
recent publication [1]. The participants’ PVs (listed in Supplementary table 1) were grouped on the 98 
basis of position within the BRCA2 gene, based on the proposed PCCR (c.7914 to 3’ [8]; HGVS 99 
nomenclature [http://varnomen.hgvs.org/]; using cDNA reference sequence NM_000059.3 and 100 
reference genome hg18) and the wide definition of the OCCR (c.2831 to c.6401) [1–4]. We 101 
additionally considered the region bounded by c.756 and c.1000 in which Patel and co-workers 102 
found evidence of increased PCa risk [8], but due to a small sample size (n=1) we could not estimate 103 
the PCa risk associated with this region. Here, we also present floating absolute risks (FARs) [9] to 104 
enable risk comparisons between any of the considered genomic regions. 105 
 106 
The Anglia and Oxford Medical Research and Ethics Committee approved the study. All participants 107 
provided written informed consent.  108 
 109 
Twenty-six participants developed PCa during median follow-up of 5.3 yr (inter-quartile range 2.6-110 
8.9 yr) [1]. Carriers of PVs in the PCCR (n=93) had a PCa standardised incidence ratio (SIR) of 8.33 111 
(95% CI 4.46-15.6), whereas carriers of PVs elsewhere in BRCA2 (n=354) had an SIR of 3.31 (95% CI 112 
1.97-5.57) compared to population incidences. This corresponds to a significantly higher PCa risk 113 
associated with PVs in the PCCR compared to non-PCCR PVs (HR=2.34, 95% CI 1.09-5.03; Table 1). 114 
Compared to PVs in the region c.1001 to c.7913 [8], PCCR PVs were associated with a HR of 2.09 115 
(95% CI 0.98-4.45). As previously reported, the SIR for carriers of PVs in the wide definition OCCR  116 
4 
 
(n=178) was 2.46 (95% 1.07-5.64) [1], and the risk for carriers of PCCR PVs was also significantly 117 
higher than that for OCCR PV carriers (HR=3.41, 95% CI 1.27-9.16). The SIR for PVs located in the 118 
region bounded by the OCCR and the PCCR (c.6402 to c.7913; n=66) was estimated to be 6.14 (95% 119 
CI 2.18-17.3), and the SIR for BRCA2 PVs upstream of the OCCR (5’ to c.2830; n=108) was 3.50 (95% 120 
CI 1.48-8.26). The FARs for the comparison of risks across the four regions suggested that the 121 
observed increased risk associated with PVs in the PCCR may be partly driven by the lower risk 122 
associated with PVs in the OCCR (Table 1). The proportional hazards assumption was violated for the 123 
model with all genomic regions fitted (Schoenfeld residuals test, p=0.003); in line with this the 124 
corresponding Kaplan—Meier plot indicated that the risks might be similar between the OCCR and 125 
PCCR PV carriers at younger ages but deviate at older ages. PCCR PV carriers had an estimated 126 
cumulative PCa risk of 44% (95% CI 23%-72%) by age 75 and 78% (95% CI 54%-94%) by age 85. After 127 
omitting the first six mo of follow-up to assess the possible effect of screening-associated diagnoses 128 
of indolent PCas, the corresponding estimates were 41% (95% CI 20%-73%) and 69% (95% CI 42%-129 
91%), respectively (Figure 1). 130 
 131 
The difference in PCa risk for PVs in PCCR vs OCCR remained statistically significant after adjusting 132 
for family history of PCa (number of first- and second-degree relatives diagnosed with PCa; adjusted 133 
HR=3.00, 95% CI 1.06-8.54) or geographical location (adjusted HR=3.79, 95% CI 1.41-10.2). This 134 
difference remained similar after omitting related individuals (HR=4.29, 95% CI 1.30-14.2), after 135 
omitting the first six mo of follow-up (HR=3.96, 95% CI 1.18-13.3), and after omitting carriers of PVs 136 
in the region c.756 to c.1000 (HR=3.42, 95% CI 1.27-9.18) or missense variants (HR=3.76, 95% CI 137 
1.36-10.4). When carriers of the Ashkenazi founder PV c.5946delT (n=42) which is located in the 138 
OCCR was omitted, the difference in PCa risk between PCCR and OCCR PV carriers was not 139 
statistically significant but the HR estimate was of similar magnitude (HR=2.89, 95% CI 0.98-8.53; 140 
Supplementary table 2).  141 
 142 
We did not observe a higher risk of Gleason score≥8 PCa for PVs in the PCCR compared to non-PCCR 143 
PVs (HR=0.87, 95% CI 0.12-6.34), or compared to PVs in the region c.1001 to c.7913 (HR=0.79, 95% 144 
CI 0.11-5.69). However, the HRs did not differ significantly from those for Gleason score≤7 PCa (PCCR 145 
vs non-PCCR: HR=3.32, 95% CI 1.25-8.84; test for heterogeneity, p=0.052; PCCR vs c.1001 to c.7913: 146 
HR=2.94, 95% CI 1.11-7.80; test for heterogeneity, p=0.088).  147 
 148 
Our results corroborate the observation that carriers of PVs in the PCCR of the BRCA2 gene [8] are at 149 
a higher risk of PCa than other BRCA2 PV carriers. Patel and co-workers reported a HR of 1.78 (95% 150 
CI 1.25-2.52) compared to PVs in the region c.1001 to c.7913 [8], consistent with our HR estimate of 151 
2.09 (95% CI 0.98-4.45). Our findings do not support a stronger association with a more aggressive 152 
phenotype, but these estimates were based on a small number of cases and have wide CIs. PV 153 
carriers may receive enhanced screening which may lead to biases in comparisons against the 154 
population incidence [1]. However, current screening practices do not differ by BRCA2 PV location 155 
and so this is unlikely to have confounded the comparisons between the BRCA2 genomic regions. A 156 
much larger cohort of unaffected carriers with longer follow-up is required to provide more precise 157 
PV-specific risk estimates, and to further clarify whether the observed variation in risk reflects lower 158 
risks associated with PVs outside the OCCR and PCCR than the risk associated with PCCR PVs, or 159 





[1] Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate Cancer Risks 163 
for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol 164 
2020;77:24–35. https://doi.org/10.1016/j.eururo.2019.08.025. 165 
[2] Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of 166 
breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. 167 
Nat Genet 1997;15:103–5. https://doi.org/10.1038/ng0197-103. 168 
[3] Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation 169 
carriers. Am J Hum Genet 2001;68:410–9. https://doi.org/10.1086/318181. 170 
[4] van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, et 171 
al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med 172 
Genet 2005;42:711–9. https://doi.org/10.1136/jmg.2004.028829. 173 
[5] Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type 174 
and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 175 
2015;313:1347–61. https://doi.org/10.1001/jama.2014.5985. 176 
[6] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks 177 
of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. 178 
JAMA 2017;317:2402–16. https://doi.org/10.1001/jama.2017.7112. 179 
[7] Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian S V, Mazoyer S. Does 180 
nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 181 
gene? Oncogene 2006;25:323–8. https://doi.org/10.1038/sj.onc.1209033. 182 
[8] Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, et al. Association of Genomic 183 
Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res 184 
2020;80:624–38. https://doi.org/10.1158/0008-5472.CAN-19-1840. 185 
[9] Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival 186 
and case-control analysis avoiding an arbitrary reference group. Stat Med 1991;10:1025–35. 187 
https://doi.org/10.1002/sim.4780100703. 188 
 189 
  190 
6 
 
Figure and Table legends 191 
 192 
Figure 1  193 
Absolute prostate cancer risk, (A) by location of BRCA2 pathogenic variant, (B) by location of BRCA2 194 
pathogenic variant and with follow-up initiated six mo after study entry.  195 
The number at risk at each age is shown above the x-axis. The curves are truncated at ages when 196 
fewer than five participants are at risk. 197 
Abbreviations OCCR: ovarian cancer cluster region; PCCR: prostate cancer cluster region. 198 
 199 
Table 1  200 
Prostate cancer risk by location of BRCA2 pathogenic variant. 201 
Abbreviations SIR: standardised incidence ratio; CI: confidence interval; HR: hazard ratio; FAR: 202 
floating absolute risk; PV: pathogenic variant; OCCR: ovarian cancer cluster region; PCCR: prostate 203 
cancer cluster region. 204 
 205 





We thank all the participants in the EMBRACE study. This work was supported by Cancer Research 209 
UK grants C12292/A20861 and C12292/A22820. EMBRACE was supported by Cancer Research UK 210 
grants C1287/A23382 and C1287/A26886. D. Gareth Evans is supported by a National Institute for 211 
Health Research grant to the Biomedical Research Centre, Manchester (IS-BRC-1215-20007). 212 
Rosalind Eeles is supported by Cancer Research UK grant C5047/A8385, and by National Institute for 213 
Health Research support to the Biomedical Research Centre at The Institute of Cancer Research and 214 
The Royal Marsden NHS Foundation Trust. 215 
 216 
Conflict of interest statement 217 
 218 
All authors declare that they have no conflict of interest. 219 
 220 
Data sharing statement 221 
 222 
The data used in the analysis are available to other researchers upon request to the EMBRACE study 223 




Figure 1 Absolute prostate cancer risk, (A) by location of BRCA2 pathogenic variant, (B) by location of BRCA2 pathogenic variant and with follow-up initiated 
six mo after study entry.  
The number at risk at each age is shown above the x-axis. The curves are truncated at ages when fewer than five participants are at risk. 
Abbreviations OCCR: ovarian cancer cluster region; PCCR: prostate cancer cluster region. 
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Table 1 Prostate cancer risk by location of BRCA2 pathogenic variant. 
Abbreviations SIR: standardised incidence ratio; CI: confidence interval; HR: hazard ratio; FAR: floating absolute risk; PV: pathogenic variant; PCCR: prostate 
cancer cluster region; OCCR: ovarian cancer cluster region. 
 
i Detailed results for carriers of PVs in the OCCR are available in a previous publication [1]. 
PV location N Person-years 
Observed 
events 




events SIR (95% CI) HR (95% CI) FAR (95% CI) 
Compared to non-PCCR PVs 
Non-PCCR 
(5' to c.7913) 
354 2029.8 15 7.39 (4.45-12.3) 4.53 3.31 (1.97-5.57) Reference  
PCCR  
(c.7914 to 3') 
93 524.6 11 21.0 (11.4-38.7) 1.32 8.33 (4.46-15.6) 2.34 (1.09-5.03)  
Compared to OCCR PVs 
5' to c.2830 108 625.8 5 7.99 (3.37-19.0) 1.43 3.50 (1.48-8.26) 1.72 (0.50-5.94) 1.72 (0.70-4.24) 
OCCR  
(c.2831 to c.6401)i 
178 1054.4 6 5.69 (2.54-12.8) 2.44 2.46 (1.07-5.64) Reference 1.00 (0.43-2.33) 
c.6402 to c.7913 66 338.8 4 11.8 (4.29-32.5) 0.65 6.14 (2.18-17.3) 3.23 (0.79-13.2) 3.23 (1.15-9.11) 
PCCR  
(c.7914 to 3') 
93 524.6 11 21.0 (11.4-38.7) 1.32 8.33 (4.46-15.6) 3.41 (1.27-9.16) 3.41 (1.96-5.95) 
Indeterminable 2        
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Supplementary table 1 List of BRCA2 pathogenic variants carried by the 447 study participants.  
The pathogenic variants are specified using HGVS nomenclature (http://varnomen.hgvs.org/), using cDNA 
reference sequence NM_000059.3 and reference genome hg18. 
Abbreviations DL: large deletion; S: splice site. 
 
Genomic level Protein level n 
c.-227-?_67+?del p.0 6 
c.-227-?_6841+?del p.0 1 
c.17_18del p.Lys6fs 1 
c.22_23del p.Arg8fs 2 
c.26del p.Pro9fs 5 
c.36dup p.Glu13* 1 
c.104_110del p.Leu35fs 2 
c.314T>G p.Leu105* 1 
c.396T>A p.Cys132* 1 
c.407del p.Asn136fs 2 
c.470_474del p.Lys157fs 1 
c.516+1G>T S 1 
c.517-2A>G S 2 
c.538_539dup p.Ser181fs 2 
c.574_575del p.Met192fs 3 
c.631+1G>A S 1 
c.631+2T>G p.Gly173fs 5 
c.658_659del p.Val220fs 4i 
c.755_758del p.Asp252fs 19 
c.765_770delinsAAACAAT p.Asn255fs 1 
c.1097T>G p.Leu366* 1 
c.1189_1190insTTAG p.Gln397fs 7 
c.1231del p.Ile411fs 1 
c.1310_1313del p.Lys437fs 3 
c.1654del p.Ser552fs 1 
c.1689G>A p.Trp563* 3 
c.1787_1799del p.Asp596fs 2 
c.1813del p.Ile605fs 3 
c.1813dup p.Ile605fs 4 
c.1889del p.Thr630fs 1 
c.1929del p.Arg645fs 7 
c.2409T>G p.Tyr803* 3 
c.2606C>G p.Ser869* 1 
c.2701del p.Ala902fs 1 
c.2760del p.Ile921fs 1 
c.2808_2811del p.Ala938fs 10 
c.2870del p.Asn957fs 1 
c.3009_3010del p.His1003fs 1 
c.3158T>G p.Leu1053* 2 
c.3195_3198del p.Asn1066fs 2 
11 
 
Genomic level Protein level n 
c.3405C>A p.Tyr1135* 1 
c.3530_3533del p.Asp1177fs 1 
c.3545_3546del p.Phe1182* 2 
c.3599_3600del p.Cys1200* 1 
c.3680_3681del p.Leu1227fs 1 
c.3785C>G p.Ser1262* 4 
c.3847_3848del p.Val1283fs 4 
c.3860del p.Asn1287fs 1 
c.4037_4038del p.Thr1346fs 1 
c.4101del p.Lys1367fs 1 
c.4137_4141del p.Ile1380fs 1 
c.4163_4164delinsA p.Thr1388fs 5 
c.4169del p.Leu1390fs 1 
c.4223del p.Gln1408fs 1 
c.4405_4409del p.Asp1469fs 1 
c.4415_4418del p.Lys1472fs 1 
c.4478_4481del p.Glu1493fs 10 
c.4525C>T p.Gln1509* 1 
c.4631dup p.Asn1544fs 1 
c.4638del p.Phe1546fs 1 
c.4648G>T p.Glu1550* 1 
c.4712_4713del p.Glu1571fs 2 
c.4828dup p.Val1610fs 1 
c.4876_4877del p.Asn1626fs 4 
c.4889C>G p.Ser1630* 2 
c.4914dup p.Val1639fs 1 
c.4936_4939del p.Glu1646fs 1 
c.4981del p.Tyr1661fs 1 
c.5073dup p.Trp1692fs 4 
c.5116_5119del p.Asn1706fs 3 
c.5141_5144del p.Tyr1714fs 1 
c.5217_5223del p.Tyr1739* 1 
c.5217T>A p.Tyr1739* 1 
c.5279C>G p.Ser1760* 2 
c.5298del p.Asn1766fs 1 
c.5303_5304del p.Leu1768fs 2 
c.5329_5334delinsG p.Lys1777fs 1 
c.5350_5351del p.Asn1784fs 2 
c.5410_5411del p.Val1804fs 1 
c.5576_5579del p.Ile1859fs 4 
c.5641_5644del p.Lys1881fs 1 
c.5655C>A p.Cys1885* 1 
c.5682C>G p.Tyr1894* 10 
c.5722_5723del p.Leu1908fs 2 
c.5835dup p.Ser1946fs 1 
12 
 
Genomic level Protein level n 
c.5857G>T p.Glu1953* 1 
c.5909C>A p.Ser1970* 6 
c.5946del p.Ser1982fs 42 
c.6049A>T p.Lys2017* 1 
c.6052_6053del p.Ser2018* 1 
c.6065C>G p.Ser2022* 1 
c.6079dup p.Arg2027fs 1 
c.6081dup p.Glu2028fs 1 
c.6275_6276del p.Leu2092fs 27i 
c.6385G>T p.Glu2129* 1 
c.6405_6409del p.Asn2135fs 1 
c.6486_6489del p.Lys2162fs 1 
c.6588_6589del p.Lys2196fs 1 
c.6591_6592del p.Glu2198fs 5 
c.6602del p.Ser2201fs 1 
c.6658_6662del p.Glu2220fs 1 
c.6757_6758del p.Leu2253fs 2 
c.6829_6833del p.Ile2278fs 1 
c.6944_6947del p.Ile2315fs 4 
c.6980del p.Leu2327* 3 
c.6996_7004delins(20) p.Cys2332fs 3 
c.7008-?_7805+?del DL 13 
c.7008-?_8331+?del DL 1 
c.7069_7070del p.Leu2357fs 5 
c.7342_7343del p.Lys2448fs 1 
c.7480C>T p.Arg2494* 4 
c.7495C>T p.Gln2499* 1 
c.7543dup p.Thr2515fs 1 
c.7558C>T p.Arg2520* 1 
c.7757G>A p.Trp2586* 6 
c.7758G>A p.Trp2586* 2 
c.7762_7764delinsTT p.Ile2588fs 4 
c.7795G>T p.Glu2599* 1 
c.7884dup p.Trp2629fs 3 
c.7934del p.Arg2645fs 1 
c.7958T>C p.Leu2653Pro 1 
c.7977-1G>C S 4 
c.7977-2_-3del S 1 
c.7988A>T p.Glu2663Val 2 
c.8113dup p.Ser2705fs 1 
c.8167G>C p.Asp2723His 6 
c.8247_8248del p.Lys2750fs 2 
c.8297del p.Thr2766fs 9 
c.8395del p.Arg2799fs 1 
c.8575del p.Gln2859fs 9 
13 
 
Genomic level Protein level n 
c.8633-?_8754+?del DL 1 
c.8633-?_9256+?del DL 2 
c.8756del p.Gly2919fs 3 
c.8878C>T p.Gln2960* 1 
c.8904del p.Val2969fs 9 
c.8945_8946del p.Lys2982fs 1 
c.8951C>G p.Ser2984* 3 
c.8956dup p.Ile2986fs 1 
c.9054_9055del p.Ser3018fs 4 
c.9069_9076del p.Asn3024fs 2 
c.9097dup p.Thr3033fs 2 
c.9117+1G>A S 1 
c.9117G>A p.Val2985fs 2 
c.9157del p.Glu3053fs 2 
c.9253dup p.Thr3085fs 2 
c.9257-2A>G S 1 
c.9294C>G p.Tyr3098* 6 
c.9357_9360del p.Ile3120fs 2 
c.9380G>A p.Trp3127* 1 
c.9382C>T p.Arg3128* 7 
c.9481A>T p.Lys3161* 1 
c.9490_9491del p.Asn3164fs 1 
c.9502-2A>C S 1 
 
 




Supplementary table 2 Prostate cancer risk by location of BRCA2 pathogenic variant: adjustments and sensitivity analyses. 
Abbreviations HR: hazard ratio; CI: confidence interval; PV: pathogenic variant; PCCR: prostate cancer cluster region; OCCR: ovarian cancer cluster region. 
 
 
i Number of first- and second-degree relatives diagnosed with prostate cancer. 
ii Location of recruiting clinic: London; South or East England; Wales, English Midlands or North England; Scotland or Ireland. 
iii Carriers for which at least one male relative was included in the study (n=94 omitted). 
iv Carriers of PVs in the BRCA2 region c.756 to c.1000 suggested to be associated with increased PCa risks by Patel et al (2020) (n=1 omitted). 
v Carriers of pathogenic missense variants (n=9 omitted).  
vi Carriers of c.5946delT (n=42 omitted). 
PV location HR (95% CI) 
HR adjusted for 
family historyi 
(95% CI) 













carriers of PVs 













Compared to non-PCCR PVs 
Non-PCCR 
(5' to c.7913) 
Reference Reference Reference Reference Reference Reference Reference Reference 
PCCR  
(c.7914 to 3') 
2.34 (1.09-5.03) 2.03 (0.89-4.61) 2.50 (1.15-5.46) 2.93 (1.23-6.97) 2.23 (0.93-5.37) 2.33 (1.09-5.01) 2.56 (1.17-5.59) 2.05 (0.94-4.48) 
Compared to OCCR PVs 
5' to c.2830 1.72 (0.50-5.94) 1.77 (0.53-5.98) 1.86 (0.47-7.36) 1.60 (0.34-7.49) 2.55 (0.63-10.3) 1.75 (0.51-6.03) 1.77 (0.51-6.17) 1.49 (0.40-5.62) 
OCCR  
(c.2831 to c.6401) 
Reference Reference Reference Reference Reference Reference Reference Reference 
c.6402 to c.7913 3.23 (0.79-13.2) 2.86 (0.65-12.7) 4.18 (0.96-18.2) 3.65 (0.67-19.7) 4.03 (0.75-21.7) 3.24 (0.80-13.2) 3.21 (0.79-13.0) 2.77 (0.61-12.5) 
PCCR  
(c.7914 to 3') 
3.41 (1.27-9.16) 3.00 (1.06-8.54) 3.79 (1.41-10.2) 4.29 (1.30-14.2) 3.96 (1.18-13.3) 3.42 (1.27-9.18) 3.76 (1.36-10.4) 2.89 (0.98-8.53) 
Indeterminable         
